FDA022-BB05

· Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for FDA022-BB05, covering 2024-05-17 to 2024-09-26. Get the full timeline:

Most recent: Clinical Trial Update: A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors [Phase 2]